carboxylase/비만증

FIELD OF THE INVENTION The present invention relates to compounds, which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type 2 diabetes, obesity, atherosclerosis and cardiovascular diseases in humans. BACKGROUND OF THE INVENTION The

FIELD OF THE INVENTION The present invention relates to compounds that inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of diseases including, but not limited to, metabolic syndrome, type 2 diabetes, obesity, atherosclerosis, and cardiovascular diseases in

FIELD OF THE INVENTION The present invention relates to compounds, which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type 2 diabetes, obesity, atherosclerosis and cardiovascular diseases in humans. BACKGROUND OF THE INVENTION The

FIELD OF THE INVENTION The present invention relates to compounds, pharmaceutical compositions, and related methods for the treatment or prevention of various diseases such as diabetes, obesity, and metabolic syndrome. BACKGROUND OF THE INVENTION The incidence of type 2 diabetes has dramatically

BACKGROUND OF INVENTION This invention relates to Acetyl-CoenzymeA Carboxylase (ACC) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, metabolic syndrome, diabetes, obesity, atherosclerosis, and cardiovascular disease in mammals,

This disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise

FIELD OF THE INVENTION The present invention concerns certain spirocyclic amides, compositions thereof, and methods of use thereof as pharmaceuticals, particularly in the treatment of obesity, metabolic syndrome, atherosclerosis, cardiovascular disease, insulin resistance, e.g., type II or

FIELD OF THE INVENTION The present invention relates to methods and compositions for treating, preventing and diagnosing disorders related to energy metabolism and the OST-PTP signaling pathway, which involves gamma-carboxylase, osteocalcin and adiponectin. Such disorders include, but are not

BACKGROUND OF THE INVENTION Obesity is a health crisis of epic proportions. The health burden of obesity, measured by quality-adjusted life-years lost per adult, has surpassed that of smoking to become the most serious, preventable cause of death. In the US, about 34% of adults have obesity, up from

BACKGROUND OF THE INVENTION Obesity is a health crisis of epic proportions. The health burden of obesity, measured by quality-adjusted life-years lost per adult, has surpassed that of smoking to become the most serious, preventable cause of death. In the US, about 34% of adults have obesity, up from

FIELD OF THE INVENTION The present invention is directed to cell-based and non-cell based methods of drug screening to identify agents, or assay agents, that reduce OST-PTP or gamma-carboxylase activity or expression, or increase the level of undercarboxylated osteocalcin or adiponectin activity or